SCHEMBL4077819

SCHEMBL4077819

C[C@@H](CO)Nc1nc(-c2ccc(Br)cc2)cs1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.59
ALDH1A1 P00352 10/20 0.59
KMT2A Q03164 8/20 0.59
MEN1 O00255 7/20 0.59
NPSR1 Q6W5P4 1/20 0.59
RAB9A P51151 10/20 0.55
LMNA P02545 9/20 0.55
NPC1 O15118 7/20 0.55
ALOX12 P18054 2/20 0.55
SMN1; SMN2 Q16637 6/20 0.45
MAPK1 P28482 2/20 0.45
GAA P10253 5/20 0.45
KDM4E B2RXH2 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MGAM O43451 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
HTT P42858 1/20 0.43
TP53 P04637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4075012 1.00 MAPT (0.59) MAPTALDH1A1KMT2AMEN1NPSR1
SCHEMBL3170512 1.00 MAPT (0.59) MAPTALDH1A1KMT2AMEN1NPSR1
SCHEMBL4076431 0.84 MEN1 (0.52) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL4082533 0.84 MAPT (0.68) MAPTALDH1A1KMT2AMEN1NPSR1
SCHEMBL3972543 0.84 MAPT (0.56) MAPTALDH1A1KMT2AMEN1NPSR1
SCHEMBL4500517 0.84 MAPT (0.56) MAPTALDH1A1KMT2AMEN1NPSR1
SCHEMBL4075123 0.84 MAPT (0.56) MAPTALDH1A1KMT2AMEN1NPSR1
SCHEMBL4079223 0.82 MAPT (0.54) MAPTALDH1A1KMT2AMEN1NPSR1
SCHEMBL3863102 0.82 MAPT (0.54) MAPTALDH1A1KMT2AMEN1NPSR1
SCHEMBL4076677 0.82 MAPT (0.54) MAPTALDH1A1KMT2AMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US disclosed
EP-2054410-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS Wyeth (US) 2009-05-06 EP disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US disclosed
WO-2008021331-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS WYETH (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR MAPT 1550/4885ALDH1A1 3334/4885KMT2A 667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.